Achieving white blood cell equity: Are the safety profiles of biosimilar and reference pegfilgrastims comparable? - Supplementary material

Supplementary Table 1. Included studies.Supplementary Table 2. Subject demographics for phase I clinical trials.Supplementary Table 3. Patient demographics for phase III clinical trials.Supplementary Table 4.<b> </b>Summary of safety results of phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 5. Summary of the most common (&gt;5% of subjects) TEAEs in phase I studies of biosimilar pegfilgrastims in healthy subjectsSupplementary Table 6. Summary of the most common (&gt;5% of subjects) TEAEs in phase III studies of biosimilar pegfilgrastims in patients with breast cancer receiving myelosuppressive chemotherapy